Bazedoxifene/conjugated estrogens
The drug combination bazedoxifene/conjugated estrogens (trade name Duavee in the US) is a medication approved by the Food and Drug Administration (FDA) for the treatment of menopause symptoms and postmenopausal osteoporosis.[1] It is a fixed-dose combination drug containing the selective estrogen receptor modulator bazedoxifene and conjugated estrogens being marketed by the pharmaceutical company Pfizer.
Combination of | |
---|---|
Bazedoxifene | Selective estrogen receptor modulator |
Conjugated estrogens | Estrogen |
Clinical data | |
Trade names | Duavee |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
ChemSpider |
|
KEGG |
Duavee was approved by the US FDA on October 3, 2013, for use as a once-daily tablet.
References
Estrogen receptor modulators | |||||||
---|---|---|---|---|---|---|---|
ER |
| ||||||
GPER |
| ||||||
|
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.